Literature DB >> 15295831

Manufacturing desire: the commodification of female sexual dysfunction.

Jennifer R Fishman1.   

Abstract

The process of bringing new drugs to market interweaves commercialism, science, clinical medicine, and governmental regulation. Through their authority and public persona as medical experts, academic clinical trial researchers studying these pharmaceuticals are integral to this process, serving as mediators between producers (the pharmaceutical companies) and consumers (clinicians and patients) of new drugs through a complex set of exchange networks. Using examples from my ethnographic research on the search for pharmaceuticals to treat what has become known as female sexual dysfunction, this paper explores the links academic researchers make with drug manufacturers and consumer markets. Academic researchers have become an integral aspect of drug development, not only by conducting clinical trial research, but also by participating in a number of other activities that assist pharmaceutical companies in identifying and creating new markets. In this paper, i examine how researchers attend professional meetings where they present clinical trial data, lecture at continuing medical education conferences, and offer themselves as ' experts' to raise awareness about disorders and their treatments. Modifying a sociology of technology approach, this paper focuses on the actors in the social network who mediate the junctions between technological producers and consumers. This extends work in this area through theorizing the linkages between exchange networks, commodification techniques, and technoscientific developments.

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Year:  2004        PMID: 15295831     DOI: 10.1177/0306312704043028

Source DB:  PubMed          Journal:  Soc Stud Sci        ISSN: 0306-3127            Impact factor:   3.885


  7 in total

1.  Pharmaceutical virtue.

Authors:  Emily Martin
Journal:  Cult Med Psychiatry       Date:  2006-06

2.  Co-ordinating 'ethical' clinical trials: the role of research coordinators in the contract research industry.

Authors:  Jill A Fisher
Journal:  Sociol Health Illn       Date:  2006-09

3.  Negotiating the boundary between medicine and consumer culture: online marketing of nutrigenetic tests.

Authors:  Paula M Saukko; Matthew Reed; Nicky Britten; Stuart Hogarth
Journal:  Soc Sci Med       Date:  2009-12-21       Impact factor: 4.634

4.  Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities.

Authors:  Jill A Fisher; Marci D Cottingham; Corey A Kalbaugh
Journal:  Soc Sci Med       Date:  2014-08-19       Impact factor: 4.634

5.  Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society.

Authors:  Vural Ozdemir; Guilherme Suarez-Kurtz; Raphaëlle Stenne; Andrew A Somogyi; Toshiyuki Someya; S Oğuz Kayaalp; Eugene Kolker
Journal:  OMICS       Date:  2009-02

Review 6.  Corporate practices and health: a framework and mechanisms.

Authors:  Joana Madureira Lima; Sandro Galea
Journal:  Global Health       Date:  2018-02-15       Impact factor: 4.185

7.  Contested psychiatric ontology and feminist critique: 'Female Sexual Dysfunction' and the Diagnostic and Statistical Manual.

Authors:  Katherine Angel
Journal:  Hist Human Sci       Date:  2012-10       Impact factor: 0.690

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.